Association of complement factor H gene polymorphisms with age-related macular egeneration susceptibility

Xiao-Feng Hao1, Li-Ke Xie1, You-Zhi Tang1

  • 1Eye Hospital of China Academy of Chinese Medical Sciences Beijing 100040, China.

Insights

Complement factor H (CFH) gene polymorphisms I62V and Y402H are associated with increased age-related macular degeneration (AMD) risk in the Chinese population. These genetic variations may influence AMD susceptibility.

Area of Science:

  • Genetics
  • Ophthalmology
  • Molecular Biology

Background:

  • Age-related macular degeneration (AMD) is a leading cause of vision loss in older adults.
  • Genetic factors, particularly those involving the complement system, are implicated in AMD pathogenesis.
  • Complement factor H (CFH) plays a crucial role in regulating complement activation.

Purpose of the Study:

  • To investigate the association between specific polymorphisms in the CFH gene (I62V and Y402H) and the risk of developing AMD.
  • To evaluate the potential role of these CFH variants as genetic markers for AMD susceptibility.

Main Methods:

  • Case-control study involving 109 AMD patients and 165 controls.
  • Genotyping of CFH I62V and Y402H polymorphisms using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP).
  • Statistical analysis including odds ratios (ORs), 95% confidence intervals (CIs), chi-squared test, haplotype analysis, and stratification by age and smoking status.

Main Results:

  • The AA genotype and A allele of the CFH I62V polymorphism were significantly associated with increased AMD risk (OR=3.75, 1.64).
  • The CT genotype and C allele of the CFH Y402H polymorphism were also identified as risk factors for AMD (OR=2.10, 1.95).
  • Haplotype analysis revealed a higher risk for AT haplotype carriers compared to GT (OR=3.91). Smoking status influenced Y402H genotype distribution.

Conclusions:

  • CFH gene polymorphisms I62V and Y402H are associated with an increased risk of AMD in the Chinese population.
  • These findings suggest that CFH genetic variations contribute to AMD susceptibility.
  • Further research may explore the functional implications of these polymorphisms in AMD pathogenesis.
Abstract

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
125
Genetic Lingo01:11

Genetic Lingo

Overview
118.5K
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
16.8K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
91